Pulmonx Corp Cash Flow Conversion Efficiency
Pulmonx Corp cash flow conversion efficiency. Based on the latest financial reports, Pulmonx Corp (LUNG) has a cash flow conversion efficiency ratio of -0.133x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.21 Million) by net assets ($39.20 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Pulmonx Corp (2013–2025)
Cash flow conversion efficiency of Pulmonx Corp from 2013 to 2025. This chart illustrates how Pulmonx Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Pulmonx Corp for real-time trading data and today's change.
Pulmonx Corp Cash Flow Conversion Ratio Explained
Pulmonx Corp cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Pulmonx Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pulmonx Corp ranked by their cash flow conversion efficiency. Also see market cap of Pulmonx Corp for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Industri Dan Perdagangan Bintraco Dharma Tbk PT
JK:CARS
|
0.014x |
|
Escar Turizm Tasimacilik Ticaret AS
IS:ESCAR
|
0.012x |
|
Vissem Electronics Co. Ltd
KQ:072950
|
0.023x |
|
EV Advanced Material Co.Ltd
KQ:131400
|
-0.068x |
|
MAG Holdings Berhad
KLSE:0095
|
-0.125x |
|
Harn Len Corporation Bhd
KLSE:7501
|
-0.012x |
|
Azevedo & Travassos S.A
SA:AZEV3
|
0.168x |
|
Salasar Techno Engineering Limited
NSE:SALASAR
|
0.024x |
Annual Cash Flow Conversion Efficiency for Pulmonx Corp (2013–2025)
The table below shows the annual cash flow conversion efficiency of Pulmonx Corp from 2013 to 2025. Review financial agility of Pulmonx Corp to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $54.12 Million | $-32.45 Million | -0.600x | -63.14% |
| 2024-12-31 | $85.81 Million | $-31.54 Million | -0.368x | -15.62% |
| 2023-12-31 | $118.31 Million | $-37.61 Million | -0.318x | -8.46% |
| 2022-12-31 | $154.01 Million | $-45.14 Million | -0.293x | -36.70% |
| 2021-12-31 | $193.24 Million | $-41.43 Million | -0.214x | -58.27% |
| 2020-12-31 | $226.13 Million | $-30.63 Million | -0.135x | -222.24% |
| 2019-12-31 | $-187.38 Million | $-20.77 Million | 0.111x | +0.81% |
| 2018-12-31 | $-167.33 Million | $-18.39 Million | 0.110x | -99.85% |
| 2017-12-31 | $-63.18K | $-4.64 Million | 73.407x | +10136.98% |
| 2016-12-31 | $-2.84 Million | $-2.03 Million | 0.717x | -25.61% |
| 2015-12-31 | $-2.65 Million | $-2.56 Million | 0.964x | +1.67% |
| 2014-12-31 | $-1.41 Million | $-1.34 Million | 0.948x | +107.46% |
| 2013-12-31 | $-1.78 Million | $-811.78K | 0.457x | -- |
About Pulmonx Corp
Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ven… Read more